Department updates» Go to news main
Dr. Abdolell's firm's software gets regulatory nods
Photo: Tim Krochak
From the Herald Business:
Dr. Abdolell got the green light from regulators in Europe and Canada for software it developed to improve screening for breast cancer.
Densitas Inc. says it has received both a medical device licence from Health Canada and the CE mark from the European Commission for its flagship product, DM-Density.
“It’s exciting to have DM-Density entering markets with such great potential for sales,” Mohamed Abdolell, the firm’s CEO and a professor at Dalhousie University, said in a news release.
“Our products will address the real clinical challenges in the mammography enterprise, focusing on key value pathways that lead to improved care for women.”
The company’s first commercial software technology, DM-Density provides precise and consistent breast density measurements from digital images taken during mammograms.
Founded in 2011, the firm earned International Organization for Standardization certification earlier this year and is working on regulatory clearances for the product in the United States.
Company representatives are in Chicago this week for the Radiological Society of North America’s annual meeting and presented the technology earlier this year at the European Congress of Radiology in Vienna.
The European appearance generated interest, and company spokeswoman Adele MacLean told The Chronicle Herald in October the firm hoped the U.S. conference would produce a similar response.
- RRF studentship application deadline Feb 3rd
- Looking for research pitches
- CSTR 2020 – Focus on Lung Screening
- Department Head Update
- Congrats Dr. Mata‑Mbemba
- Psychotic symptoms are associated with lower cortical folding in youth at risk for mental illness
- Experience with compressed gelfoam plugs in children during liver biopsies and other IR procedures: a retrospective single‑center case series
- Dr. Efford new Modality Lead for CT
comments powered by Disqus